The Pharmacopoeia Commission for Indian Medicine & Homoeopathy (PCIM&H) under the Ministry of Ayush has completed a five-day National Capacity Building Training Programme aimed at upgrading quality assurance and regulatory capabilities in the Ayurveda, Siddha, Unani and Homoeopathy (ASU&H) drug sector. Held from 24–28 November 2025, the programme brought together drug enforcement officers, quality-control personnel and manufacturers from across the country.
Training focus and technical sessions
Over the first two days, participants attended intensive sessions on NABL accreditation, quality management systems, Good Manufacturing Practices, and pharmacognostic, physico‑chemical and phytochemical evaluation techniques for herbal drugs. Subsequent modules covered shelf‑life studies, regulatory frameworks and practical approaches to quality control of ASU&H formulations.
Industry visits and hands-on learning
The programme included field visits to leading manufacturers such as Dr. Willmar Schwabe India Pvt. Ltd. in Noida and Hamdard Laboratories in Ghaziabad, giving participants exposure to large‑scale production and quality systems. Hands‑on laboratory training in microbiological and pharmacological evaluation, along with a visit to an herbal garden, reinforced classroom learning with practical demonstrations of testing and standardisation methods.
Participation and expert guidance
Thirty‑seven participants from regulatory bodies, research councils, pharmaceutical companies and academic institutions took part in the training, gaining first‑hand insight into emerging tools and protocols in traditional medicine quality control. The valedictory session featured senior dignitaries including Prof. (Dr.) B. L. Mehra, Chairperson of the National Commission for Indian System of Medicine, as well as experts from the Indian Pharmacopoeia Commission, FSSAI and PCIM&H, who stressed the need for rigorous, science‑based standards to enhance global acceptance of Indian systems of medicine.
Impact on ASU&H quality ecosystem
Participants reported that the mix of theory, lab work and industry exposure significantly improved their understanding of pharmacopoeial standards, GMP requirements and regulatory expectations for ASU&H drugs. The initiative is expected to help build a more robust national quality‑assurance ecosystem for traditional medicines, supporting safer products, better compliance and stronger credibility in domestic and international markets.
For more real-time updates, visit Channel 6 Network.
Source: PIB
